Since the initial observation that agonistic anti-4-1BB antibodies promote tumor regression in mice [12], a large number of studies have shown efficacy of 4-1BB stimulation in anti-cancer therapies (Reviewed in [13], [14]). Here, TNFRSF9 is linked to cancer.